pro-mitotic selective MPS1 kinase inhibitor

dev. paused for 2nd candidate (BAY1217389)

from 2M cmpd biochem. HTS and SBDD

J. Med. Chem., Apr. 27, 2020

Bayer AG, Berlin, DE

BAY1161909

BAY1161909 is one of two clinical candidates disclosed in a single paper from Bayer. The compounds have an interesting anti-cancer mechanism – rather than inhibiting cancer cell growth, they accelerate…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: